Travere pays Everest $112M upfront to grow rare kidney disease pipeline

Eric Dube, Travere Therapeutics CEO June 2, 2026 09:55 AM EDTUpdated 01:33 PM DealsChinaPharma Tra­vere pays Ever­est $112M up­front to grow rare kid­ney dis­ease pipeline Kyle LaHucik Biotech Correspondent Tra­vere Ther­a­peu­tics is en­list­ing the help of Chi­na-based Ever­est Med­i­cines to bol­ster its rare kid­ney dis­ease pipeline be­yond its ap­proved med­i­cine Filspari. The San Diego … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER